KeyCorp (NYSE:KEY) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.52 by 3.85 percent. This is a 25 percent decrease over earnings of $0.72 per share from the same period last year.
Jefferies Initiates Coverage On Provention Bio with Buy Rating, Announces Price Target of $10
Jefferies analyst Chris Howerton initiates coverage on Provention Bio (NASDAQ:PRVB) with a Buy rating and announces Price Target of $10.